Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.

摘要

Sir - Bevacizumab is a monoclonal antibody that recognises vascular endothelial growth factor receptor A and has been shown to increase overall survival when added to standard chemotherapy regimens in patients with metastatic colorectal cancer. Its toxicity profile is different from standard chemotherapy. Among its risk factors, idiopathic gastrointestinal perforation is a recognised hazard: a 28 day free period between the operation and drug initiation is recommended. We have encountered a late anastomotic dehiscence 3 years after surgery.